In patients administered HER2-targeted immunotherapies, improved responses are associated with higher tumor infiltration of NK cells (1–3) or lymphocytes (4,5) in HER2-positive breast cancer biopsies. The gene discussed is ERBB2; the disease is breast carcinoma.